07 November 2016
By Dr Wendy Winnall - PCFA Research Team
Immunotherapy for cancer has been one of the most important recent breakthroughs. Drugs such as pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy) have greatly improved survival rates from a number of cancers. It was therefore very disappointing that the first trials of these drugs did not show significant benefit for men with prostate cancer. However two new trials of pembrolizumab have promising early results, renewing our hope that it can also help save prostate cancer patients.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
